Dr. Tamás Rácz
1978 MD from University of Debrecen
1982 Board cert. of oto-,rhino-, laryngology
1991 Board cert. of plastic surgery
1991 PhD from Hungarian Academy of Science Tumor Immunbiology
1999 MSc from Semmelweis University Health Management
2005- Szent Donat Hosp. (300 beds, 2 000 Op/yr) CEO and owner
2007- Stratoxer(s) Ltd. (Pharmaceutical development Ltd) CEO and owner
1992-98 R-Klinika Co. (First private clinic in Hungary) CEO and owner
1992-94 Health Reform Committee Ministry of Health Member
1994-96 Hungarian Doctor Periodical Editorial Board Member
1984-92 Associate Professor of the Dept. of Head and Neck Surgery of the National Cancer Institute Hungary
1985 Deputy of a private praxis in Augsburg, West-Germany
1988-89 Fulbright Scholar in the University of Texas, Houston M.D. Anderson Cancer Center, Department of Head and Neck Surgery USA
1978-84 Assistant Professor in the Medical University of Debrecen, Dept. Oto-, rhino-, laryngology Hungary
Schantz SP, Savage HE, Racz T, Taylor DL, Sacks PG. Natural killer cells and metastases from pharyngeal carcinoma. The American Journal of Surgery 1989; 158(4):361-6
Schantz SP, Savage HE, Racz T, Liu FJ, Brown BW, Rossen RD, Hong WK. Immunologic determinants of head and neck cancer response to induction chemotherapy. Journal of ClinicalOncology 7, No. 7 (July 01,1989) 17:857-864.
Racz T, Sacks PG, Taylor DL, Schantz SP. Natural killer cell lysis of head and neck cancer .Archives Otolaryngology Head and Neck Surgery 1989; 115(11):1322-1328.
Racz T, Van NT, Sacks PG, Ordonez NG, Schantz SP. Differential sensitivity of head and neck cancers to non-major histocompatibility restricted killer cell activity Proc. Am. Assoc. Cancer.
Res. 1989; 30: 338-348
Racz T, Sacks PG, Van NT, Taylor DL, Young G, Bugis S, Savage HE, Schantz SP. The analysis of natural killer cell activity by flow cytometry. Archives Otolaryngology Head and Neck Surgery 1990 116(4):440-446.
Bugis SP, Lotzova E, Savage HE, Hester JP, Racz T, Sacks PG, Schantz SP. Inhibition of LAK generation by blocking factors in sera of patients with head and neck cancer. Cancer Immunology Immunotherapy 1990; 31:176-181.
Sacks PG, Taylor DL, Racz T, Schantz SP. A multicellular spheroid model to study non-major histocompatibility restricted immune function against head and neck cancer. Cancer Immunology Immunotherapy 1990; 32:195-201.
Schantz SP, Clayman G, Racz T, Savage HE, Taylor DL, Liu FJ, Grimm EA. The In Vivo Biologic Effect of Interleukin 2 and Interferon Alfa on Natural Immunity in Patients With Head and Neck Cancer Archives of Otolaryngology - Head and Neck Surgery 1990; 116(11):1302-8
Schantz SP, Racz T, Ordonez NG, Terry NHA, Taylor DL, Bugis S, Sacks PG. Differential sensitivity of head and neck cancers to non-major histocompatibility restricted killer cell activity. Journal of Surgical Research 1990; 48:154-164.
Sacks PG, Racz T, Schantz SP, Rosenblum MG. Growth inhibition by b and g interferon of MDA 886Ln monolayer cells and multicellular tumor spheroids (MTS): a differentiation therapy model for squamous cell carcinoma. Archives of Otolaryngology: Head and Neck Surgery 1994; 120(11):1267-1272.